Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | PRKCI | P41743 | 2/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7940769 | 0.89 | BACE1 (0.59) | BACE1KITBRAFGRM4HDAC1 | |
| SCHEMBL12303675 | 0.87 | BACE1 (0.50) | BACE1PRKCIMALT1 | |
| SCHEMBL12303619 | 0.86 | BACE1 (0.44) | BACE1KITBRAFGRM4HDAC1 | |
| SCHEMBL7944261 | 0.85 | BACE1 (0.46) | BACE1KITBRAFPRKCIMALT1 | |
| SCHEMBL7945304 | 0.82 | BACE1 (0.50) | BACE1GRM4KCNH2 | |
| SCHEMBL7932754 | 0.79 | BACE1 (0.55) | BACE1PRKCIGRM4HDAC1 | |
| SCHEMBL7943492 | 0.78 | BACE1 (0.52) | BACE1KITBRAFPRKCIHDAC1 | |
| SCHEMBL7932664 | 0.78 | BACE1 (0.46) | BACE1KITBRAFPRKCIGRM4 | |
| SCHEMBL7935620 | 0.78 | BACE1 (0.53) | BACE1PRKCIGRM4HDAC1 | |
| SCHEMBL7941379 | 0.78 | BACE1 (0.53) | BACE1PRKCIGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885KIT 4123/4885BRAF 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.